title: High ficolin-3 level at the time of transplantation is an independent risk factor for graft loss in kidney transplant recipients.
abstract: BACKGROUND
  Recent studies have shown that activation of the complement system may be associated with long-term graft function. The aim of this retrospective study was to assess the impact of the pattern recognition molecules of the lectin pathway on long-term graft survival after kidney transplantation.
  
  
  METHODS
  Patients transplanted in 2000 to 2001 were included. Mannose-binding lectin, Ficolin-1, and Ficolin-3 were measured in serum at the time of transplantation. Data on death-censored graft loss were obtained from the Norwegian Renal Registry. Competing risks regression was used to investigate the association between time to graft loss and the explanatory variables. The variables were: high Ficolin-3 (upper quartile, ≥33.3 μg/mL) versus low Ficolin-3 (<33.3 μg/mL), acute rejection (time-dependent), age, basiliximab induction, sex, donor age, human leukocyte antigen mismatches, human leukocyte antigen antibodies, cold ischemia time, living donor, and preemptive transplantation.
  
  
  RESULTS
  A total of 382 patients with a median follow-up of 9.8 years were included. Sixty-six patients (17%) had death-censored graft loss, and 116 (30%) patients died. In a final competing risks model, high Ficolin-3 (subhazard ratio [SHR] = 1.95, P = 0.009), acute rejection (one vs. none) (SHR = 1.93, P = 0.033), acute rejection (two vs. none) (SHR = 5.45, P < 0.001), and age (SHR = 0.98, P = 0.006) were associated with death-censored graft loss. Basiliximab induction was associated with improved graft survival (SHR = 0.50, P = 0.016). No associations between mannose-binding lectin or Ficolin-1 and graft loss were found.
  
  
  CONCLUSIONS
  High Ficolin-3 level at the time of transplantation was an independent significant risk factor for shorter graft survival, even when adjusted for other covariates.
authors.affiliation: 1 Department of Nephrology, Ullevål Oslo University Hospital, Oslo, Norway. 2 Department of Transplant Medicine, Rikshospitalet Oslo University Hospital, Oslo, Norway. 3 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 4 Unit of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. 5 Department of Microbiology, Rikshospitalet Oslo University Hospital, Oslo, Norway. 6 Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway. 7 K.G Jebsen IRC, University of Oslo, Norway. 8 Research Laboratory, Nordland Hospital, Bodø, and Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. 9 Department of Biomedicine, Aarhus University, Aarhus, Denmark.
authors.forename: Yuliya V
authors.initials: YV
authors.lastname: Smedbråten
authors.forename: Solbjørg
authors.initials: S
authors.lastname: Sagedal
authors.forename: Geir
authors.initials: G
authors.lastname: Mjøen
authors.forename: Anders
authors.initials: A
authors.lastname: Hartmann
authors.forename: Morten W
authors.initials: MW
authors.lastname: Fagerland
authors.forename: Halvor
authors.initials: H
authors.lastname: Rollag
authors.forename: Tom Eirik
authors.initials: TE
authors.lastname: Mollnes
authors.forename: Steffen
authors.initials: S
authors.lastname: Thiel
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006084:Graft Rejection / Q000097:blood / Q000276:immunology* / Q000401:mortality; D006085:Graft Survival; D006785:Hospitals, University; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009664:Norway; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; C109662:FCN3 protein, human; D006023:Glycoproteins; D037102:Lectins